Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2015

Open Access 01-12-2015 | Letter to the Editor

Identification of ANLN as ETV6 partner gene in recurrent t(7;12)(p15;p13): a possible role of deregulated ANLN expression in leukemogenesis

Authors: Paulo Vidal Campregher, Welbert de Oliveira Pereira, Bianca Lisboa, Renato Puga, Ricardo Helman, Mariana Miyagi, Evelyn Helena Ascendino da Mata, Tarcila Santos Datoguia, Elvira Deolinda Rodrigues Pereira Velloso, Nydia Strachman Bacal, Jeffrey S. Ross, Siraj Ali, Vincent Miller, Fernando Ferreira Costa, Nelson Hamerschlak, Fabio Pires de Souza Santos

Published in: Molecular Cancer | Issue 1/2015

Login to get access

Abstract

The ETV6 gene encodes an ETS family transcription factor that is involved in a myriad of chromosomal rearrangements found in hematological malignancies and other neoplasms. A recurrent ETV6 translocation, previously described in patients with acute myeloid leukemia (AML) (Genes Chromosomes Cancer 51:328–337,2012, Leuk Res 35:e212-214, 2011), whose partner has not been identified is t(7;12)(p15;p13). We herein report that the t(7;12)(p15;p13) fuses ETV6 to ANLN, a gene not previously implicated in the pathogenesis of hematological malignancies, and we demonstrate that this translocation leads to high expression of the fusion transcript in the myeloid and lymphoid lineages.
Literature
1.
De Braekeleer E, Douet-Guilbert N, Morel F, Le Bris MJ, Basinko A, De Braekeleer M. ETV6 fusion genes in hematological malignancies: a review. Leuk Res. 2012;36(8):945–61.CrossRefPubMed
2.
Yamamoto K, Yakushijin K, Funakoshi Y, Inui Y, Okamura A, Matsuoka H, et al. Biallelic ETV6 rearrangements by recurrent translocations t(7;12)(p15;p13) and t(3;12)(q26.2;p13) in acute myeloid leukemia. Leuk Res. 2011;35(11):e212–214.CrossRefPubMed
3.
Haferlach C, Bacher U, Schnittger S, Alpermann T, Zenger M, Kern W, et al. ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events. Genes Chromosomes Cancer. 2012;51(4):328–37.CrossRefPubMed
4.
Oegema K, Savoian MS, Mitchison TJ, Field CM. Functional analysis of a human homologue of the Drosophila actin binding protein anillin suggests a role in cytokinesis. J Cell Biol. 2000;150(3):539–52.PubMedCentralCrossRefPubMed
5.
Zhao WM, Fang G. Anillin is a substrate of anaphase-promoting complex/cyclosome (APC/C) that controls spatial contractility of myosin during late cytokinesis. J Biol Chem. 2005;280(39):33516–24.CrossRefPubMed
6.
Suzuki C, Daigo Y, Ishikawa N, Kato T, Hayama S, Ito T, et al. ANLN plays a critical role in human lung carcinogenesis through the activation of RHOA and by involvement in the phosphoinositide 3-kinase/AKT pathway. Cancer Res. 2005;65(24):11314–25.CrossRefPubMed
7.
Zhou W, Wang Z, Shen N, Pi W, Jiang W, Huang J, et al. Knockdown of ANLN by lentivirus inhibits cell growth and migration in human breast cancer. Mol Cell Biochem. 2014. [Epub ahead of print]
8.
Hall PA, Todd CB, Hyland PL, McDade SS, Grabsch H, Dattani M, et al. The septin-binding protein anillin is overexpressed in diverse human tumors. Clin Cancer Res. 2005;11(19 Pt 1):6780–6.CrossRefPubMed
Metadata
Title
Identification of ANLN as ETV6 partner gene in recurrent t(7;12)(p15;p13): a possible role of deregulated ANLN expression in leukemogenesis
Authors
Paulo Vidal Campregher
Welbert de Oliveira Pereira
Bianca Lisboa
Renato Puga
Ricardo Helman
Mariana Miyagi
Evelyn Helena Ascendino da Mata
Tarcila Santos Datoguia
Elvira Deolinda Rodrigues Pereira Velloso
Nydia Strachman Bacal
Jeffrey S. Ross
Siraj Ali
Vincent Miller
Fernando Ferreira Costa
Nelson Hamerschlak
Fabio Pires de Souza Santos
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2015
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/s12943-015-0471-5

Other articles of this Issue 1/2015

Molecular Cancer 1/2015 Go to the issue

Research

Targeting TR4 nuclear receptor suppresses prostate cancer invasion via reduction of infiltrating macrophages with alteration of the TIMP-1/MMP2/MMP9 signals

Research

Male-specific hepatitis B virus large surface protein variant W4P potentiates tumorigenicity and induces gender disparity

Research

High expression of protein phosphatase 4 is associated with the aggressive malignant behavior of colorectal carcinoma

Research

The polarity protein Scrib mediates epidermal development and exerts a tumor suppressive function during skin carcinogenesis

Research

Targeting PBK/TOPK decreases growth and survival of glioma initiating cells in vitro and attenuates tumor growth in vivo

Research

Microenvironmental effects limit efficacy of thymoquinone treatment in a mouse model of ovarian cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits